vTv Therapeutics Inc - Ordinary Shares - Class A

NASDAQ:VTVT   12:07:45 PM EDT
1.40
-0.02 (-1.76%)
Products, Regulatory, Earnings Announcements

Vtv Therapeutics Announces Results For Hpp737, An Oral Pde4 Inhibitor For The Treatment Of Psoriasis

Published: 09/23/2021 20:47 GMT
vTv Therapeutics Inc - Ordinary Shares - Class A (VTVT) - Vtv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for Hpp737, an Oral Pde4 Inhibitor for the Treatment of Psoriasis.
Vtv Therapeutics Inc - Hpp737 Exhibited Favorable Safety and Tolerability Profile, With No Dose Limiting Gastrointestinal Side Effects.
Vtv Therapeutics Inc - Results Support Advancement of Hpp737 Into Phase 2 in Moderate to Severe Psoriasis.
Vtv Therapeutics - Successful Pre-ind Meeting With U.S. FDA Division of Dermatology and Dentistry Supports Planned Ind Submission for a Phase 2 Study.
Revenue is expected to be $1.3 Million
Adjusted EPS is expected to be -$0.07

Next Quarter Revenue Guidance is expected to be $2.8 Million
Next Quarter EPS Guidance is expected to be -$0.07

More details on our Analysts Page.